IMGN News and Press, ImmunoGen Inc. From 12/31/19

ImmunoGen Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on December 23, 2019 the compensation committee of the Company’s Board of Directors granted a non-qualified stock option award to purch...

Penny Stocks Can Breakout Big After News; These Haven’t Stopped Investing in penny stocks can often prove to be one of the most thrilling experiences for any investor. That’s considering the fact that these cheap stocks have the potential of generating enormous returns. Howev...

TRACON Pharmaceuticals (NASDAQ: TCON )  +25%  on envafolimab deal . More news on: TRACON Pharmaceuticals, Inc., Care.com, Inc., Marinus Pharmaceuticals, Inc., Stocks on the move, Read more ...

More often than not, seasoned money managers say that investors should explore a range of growing sectors and then choose specific stocks. The same holds true when it comes to penny stocks . Though your average money manager might not recommend these cheap stocks in a long-term portfolio, inves...

December 18, 2019 Palm Beach, FL – December 18, 2019 – Back in the end of 2018, a report from Moody’s said that 2019 should be a standout year for the medical device industry. They added that revenue growth for device companies would be driven through innovation...

Editor's note: Seeking Alpha is proud to welcome Vince Yeh as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to SA PREMIUM. Click here to find out more » Editor's note: Seeking...

ImmunoGen (NASDAQ: IMGN ) announces that the FDA has advised that a new single-arm study in platinum-resistant ovarian cancer could support accelerated approval for mirvetuximab soravtansine. More news on: ImmunoGen, Inc., Healthcare stocks news, Stocks on the move, Read more .....

Top-Line Data from New Pivotal Single-Arm Trial, SORAYA, Expected in First Half of 2021 Confirmatory MIRASOL Trial for Mirvetuximab on Track to Start by Year-End Conference Call to be Held at 8:00 a.m. ET Today ImmunoGen Inc. , (Nasdaq: IMGN), a leader in the expanding fie...

The following slide deck was published by ImmunoGen, Inc. in conjunction with this Read more ...

Data Demonstrating Potential in AML and BPDCN Presented During Oral Presentation; Dose and Schedule Selected for Further Development Preclinical Combination Data Also Presented; Support Further Evaluation of IMGN632 Doublets and Triplet in AML ImmunoGen, Inc. , (Nasdaq: IMGN) a l...